RxDoctor Payments Data

Daniel Hayward, MD

Internal Medicine · Bridgman, MINPI 1285679365

Payments from drug & device makers

$960in general payments, 2019–2025

Across 47 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$274
  • Novo Nordisk$268
  • Astellas Pharma US Inc$190
  • AbbVie$115
  • Amgen$37
  • Merck$30
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$86090%
  • Education$10010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$960 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$123,267
Medicare patients
656
Services billed
1,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$203,624
TrulicityDulaglutide123$187,172
OzempicSemaglutide104$152,903
JardianceEmpagliflozin73$96,490
XareltoRivaroxaban39$51,163
MyrbetriqMirabegron49$41,378
FarxigaDapagliflozin Propanediol32$34,072
JanuviaSitagliptin Phosphate22$33,096
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$32,516
MounjaroTirzepatide11$20,909
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$18,209
Atorvastatin Calcium1,129$14,705
EntrestoSacubitril/Valsartan17$12,148
Irbesartan408$11,873
Breo ElliptaFluticasone/Vilanterol24$11,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$11$208,904178 claims
Novo NordiskOzempic$268$152,903104 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$274$50,73578 claims
Astellas Pharma US IncMyrbetriq$190$41,37849 claims
MerckJanuvia$30$33,09622 claims
AbbVieSynthroid, Lumigan$115$7,10864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Bridgman

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →